EKF Diagnostics (LON:EKF) Given “Buy” Rating at Stifel Nicolaus

EKF Diagnostics (LON:EKF)‘s stock had its “buy” rating reaffirmed by Stifel Nicolaus in a research note issued on Wednesday,London Stock Exchange reports. They currently have a GBX 35 price target on the stock. Stifel Nicolaus’ target price points to a potential upside of 37.25% from the stock’s current price.

EKF Diagnostics Trading Up 3.7%

LON:EKF traded up GBX 0.90 during mid-day trading on Wednesday, hitting GBX 25.50. 36,746 shares of the company’s stock were exchanged, compared to its average volume of 421,409. The company has a 50 day simple moving average of GBX 24.91 and a 200-day simple moving average of GBX 25.55. The company has a current ratio of 4.16, a quick ratio of 1.77 and a debt-to-equity ratio of 2.01. EKF Diagnostics has a fifty-two week low of GBX 19 and a fifty-two week high of GBX 32. The firm has a market capitalization of £109.93 million, a P/E ratio of 54.26 and a beta of 0.49.

EKF Diagnostics (LON:EKF) last posted its earnings results on Tuesday, March 24th. The company reported GBX 0.47 EPS for the quarter. EKF Diagnostics had a net margin of 4.12% and a return on equity of 3.01%. As a group, research analysts expect that EKF Diagnostics will post 2.2987842 earnings per share for the current year.

About EKF Diagnostics

EKF is an AIM-listed global diagnostics business focussed on:

● Point-of-Care analysers in the key areas of Hematology and Diabetes

● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.